Rather, positive schedule-dependent combination anti-tumour activity of adavosertib + anti-PD-L1 is observed, including 3/10 complete responses (CR) with the combination using a schedule that showed no CR with either monotherapy. This evidence concerns the gene CD274 and neoplasm.